A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
暂无分享，去创建一个
H. Nahi | A. Waage | M. Hansson | L. Ahlberg | B. Lauri | F. Schjesvold | K. Carlson | M. Putkonen | S. Ilveskero | M. Klimkowska | M. Sankelo | P. Anttila | R. Silvennoinen | R. Matuzevičienė | M. Säily | D. Szatkowski | V. Pečeliūnas | J. Abelsson | M. Mikkola | Anu Marttila | A. Sikiö | A. Partanen | E. Ahlstrand | P. Axelsson | E. Haukaas | Conny Karlsson | Mona Hoysaeter Fenstad